Eye Opener by ExSight Ventures

In this episode of The Eye Opener, we spotlight a major milestone for ONL Therapeutics, an ExSight Ventures portfolio company since 2018, as the company announced it randomized its first patient in the Phase 2 GALAXY trial.Join ONL CEO David Esposito, COO Connie Chang, and ExSight Ventures Managing Partner James Murray as they explore the power of teamwork and leadership in biotech, and the road to bringing xelafaslatide (formerly ONL1204) into the clinic for patients suffering from geographic atrophy (GA) due to dry age-related macular degeneration (AMD). Topics covered:How collaboration in the C-suite is an essential component of any life science and biopharma startup. Lessons from advancing a novel therapy to human trialsThe importance of adaptability and communication in ONL's journey Listen now for insights at the intersection of ophthalmology, biotech innovation, and venture capital — and discover how teamwork drives ONL's pursuit of breakthroughs that could preserve sight for millions.

A new discussion series hosted by ExSight Ventures. The series will focus on early stage innovation from various perspectives through discussions with key stakeholders from across the innovation spectrum; researchers to founders, to strategic partners. And tonight we'll dive into the world of early stage of ophthalmic innovation from our perspective, as a venture capital firm dedicated to investing in the space and bringing transformative technologies to patients and clinicians.